Compare GEL & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEL | GLPG |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 1996 | 2005 |
| Metric | GEL | GLPG |
|---|---|---|
| Price | $16.46 | $34.35 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | $19.50 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 251.7K | 124.5K |
| Earning Date | 02-12-2026 | 02-17-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,893,959,000.00 | $336,643,201.00 |
| Revenue This Year | N/A | $1.76 |
| Revenue Next Year | $19.09 | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.14 | 10.31 |
| 52 Week Low | $10.29 | $22.36 |
| 52 Week High | $17.77 | $37.78 |
| Indicator | GEL | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 48.91 | 60.50 |
| Support Level | $16.33 | $34.18 |
| Resistance Level | $17.60 | $35.06 |
| Average True Range (ATR) | 0.51 | 0.72 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 16.43 | 71.67 |
Genesis Energy LP is a limited partnership company that focuses on the midstream segment of the crude oil and natural gas industry. It engages in providing services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are offshore pipeline transportation, sodium minerals, and sulfur services, onshore facilities and transportation, and marine transportation. It generates maximum revenue from the offshore pipeline transportation segment which conducts crude oil and natural gas pipeline transportation and handling operations in the Gulf of Mexico through its offshore pipeline transportation segment, which focuses on providing a suite of services to integrated and large independent energy companies.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.